- Home
- PR vs BBIO Comparison
PR vs BBIO Comparison
Compare PR & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PR | BBIO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 15.3B |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PR | BBIO |
|---|---|---|
| Price | $19.32 | $69.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 24 |
| Target Price | $20.31 | ★ $83.00 |
| AVG Volume (30 Days) | ★ 11.8M | 2.8M |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $5,065,211,000.00 | $502,076,000.00 |
| Revenue This Year | $5.54 | $88.86 |
| Revenue Next Year | $11.09 | $74.11 |
| P/E Ratio | $14.92 | ★ N/A |
| Revenue Growth | 1.29 | ★ 126.26 |
| 52 Week Low | $10.62 | $28.33 |
| 52 Week High | $19.64 | $84.94 |
Technical Indicators
Market Signals| Indicator | PR | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 66.64 | 49.17 |
| Support Level | $12.43 | $61.95 |
| Resistance Level | N/A | $79.56 |
| Average True Range (ATR) | 0.60 | 3.33 |
| MACD | -0.01 | 0.53 |
| Stochastic Oscillator | 88.38 | 50.86 |
Price Performance
Historical ComparisonAbout PR Permian Resources Corporation
Permian Resources Corp is an independent oil and natural gas company focused on generating outsized returns to stakeholders through the responsible acquisition, optimization, and development of oil and liquids-rich natural gas assets. The Company's assets and operations are concentrated in the core of the Permian Basin, and its properties consist of large, contiguous acreage blocks located in West Texas and New Mexico.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.